Galera | Jotup

Galera to Present at Jefferies Healthcare Conference

Retrieved on:

Thursday, June 2, 2022

Galera, Large-cell lung carcinoma, Conference, Webcast, Investor, Pancreatic cancer, Nasdaq, Therapy, GLOBE, Patient, GC4419, Event, Cancer, Pharmaceutical industry

A live webcast of the presentation will be accessible from the Investors page of Galeras website, investors.galeratx.com .

Key Points:

A live webcast of the presentation will be accessible from the Investors page of Galeras website, investors.galeratx.com .
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer.
Galeras selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities.
Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com .

Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

Wednesday, April 27, 2022

The titles of the abstracts are currently available in the ASCO digital program , with the full abstracts scheduled to be published on May 26, 2022, at 5 p.m. EDT.

Key Points:

The titles of the abstracts are currently available in the ASCO digital program , with the full abstracts scheduled to be published on May 26, 2022, at 5 p.m. EDT.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer.
Galeras selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities.
Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com .

Galera to Present at H.C. Wainwright BioConnect Conference

Retrieved on:

Thursday, January 6, 2022

Baozou Big News Events, Therapy, Large-cell lung carcinoma, Galera, News, Investor, Pancreatic cancer, Patient, Webcast, Cancer, GC4419, Conference, GLOBE, Nasdaq, Pharmaceutical industry

A webcast of the presentation will be available for on-demand viewing on January 10, 2022 at 7:00 a.m.

Key Points:

A webcast of the presentation will be available for on-demand viewing on January 10, 2022 at 7:00 a.m.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer.
Galeras selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities.
Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com .

Nanocan Therapeutics Corporation Appoints Renowned Oncologist Dr. Elizabeth Charlotte Moser as Chief Scientific Officer

Retrieved on:

Tuesday, September 28, 2021

Drug development, Therapy, Galera, Cancer, Patient, Champalimaud Foundation, Elekta, Entrepreneurship, Targanta Therapeutics Corporation, Pharmaceutical industry, Medical device

PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ --Nanocan Therapeutics Corporation (Nanocan), a clinical stage biotechnology company developing innovative cancer treatments, announced the appointment of Dr. Elizabeth Charlotte Moser, as its Chief Scientific Officer and member of the company's executive leadership team.

Key Points:

PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ --Nanocan Therapeutics Corporation (Nanocan), a clinical stage biotechnology company developing innovative cancer treatments, announced the appointment of Dr. Elizabeth Charlotte Moser, as its Chief Scientific Officer and member of the company's executive leadership team.
Dr. Moser is an internationally recognized leader in oncology, with extensive expertise in clinical and translational research in combination cancer treatments.
"Dr. Moser is an accomplished and well-respected scientist whose deep foundational knowledge will, no doubt, position us well for success," said Eric Broyles, Co-Founder and Chief Executive Officer of Nanocan.
Before joining Nanocan Dr. Moser served as the vice president for clinical development at Galera Therapeutics.

Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer

Retrieved on:

Tuesday, September 14, 2021

MALVERN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that the Company will host a virtual Key Opinion Leader event on radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer on Thursday, September 23 at 11:00 a.m. ET.

Key Points:

Dr. Andersons presentation will be followed by a video from a head and neck cancer survivor on his experience with SOM and a presentation from Galeras President and CEO, Mel Sorensen, M.D., with an overview of the SOM market in patients with head and neck cancer.
The live audio webcast of the event will be accessible from the News & Events section of the Investors page of Galeras website at investors.galeratx.com .
Galeras lead product candidate is avasopasem manganese (avasopasem, or GC4419), a selective small molecule dismutase mimetic in late-stage development to reduce the incidence and severity of radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer.
Avasopasem is also in development for radiotherapy-induced esophagitis in patients with lung cancer.

Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Retrieved on:

Wednesday, May 5, 2021

Antioxidants, Mucositis, Radiation therapy, Superoxide dismutase mimetics, Physical sciences, Galera, Natural sciences, Physics

Galera\xe2\x80\x99s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).

Key Points:

Galera\xe2\x80\x99s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).
The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy.
Galera also intends to initiate the GRECO-2 Phase 2b trial of GC4711 in combination with SBRT in patients with LAPC.
Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com .\n'

Codership Releases Galera Manager To Easily Deploy And Manage Galera Cluster On Amazon Web Services

Retrieved on:

Wednesday, September 30, 2020

Database management systems, Databases, MySQL, Data management, Galera, Percona, XtraDB, MariaDB, Amazon Web Services, Aria, MySQL Cluster

HELSINKI, Sept. 30, 2020 /PRNewswire/ --Codership, the leading MySQL and MariaDB High Availability clustering solutions company behind Galera Cluster, is pleased to announce the availability of Galera Manager, a web-based GUI-driven tool to easily deploy Galera Clusters in Amazon Web Services (AWS) EC2 environments.

Key Points:

HELSINKI, Sept. 30, 2020 /PRNewswire/ --Codership, the leading MySQL and MariaDB High Availability clustering solutions company behind Galera Cluster, is pleased to announce the availability of Galera Manager, a web-based GUI-driven tool to easily deploy Galera Clusters in Amazon Web Services (AWS) EC2 environments.
Databases are deployed more and more in the cloud and we wanted to support Galera users with an easy to use deployment tool that works on Amazon Web Services.
Now our users can monitor and manage their Galera Clusters through a graphical interface," says Alexey Yurchenko, President of Codership.
Galera is an open-source product and it powers MariaDB Galera Cluster and Percona XtraDB Cluster.

Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

Retrieved on:

Tuesday, December 10, 2019

Galera

2019 has been a momentous year for Galera, culminating in the closing of our IPO last month, said Mel Sorensen, M.D., President and CEO of Galera.

Key Points:

2019 has been a momentous year for Galera, culminating in the closing of our IPO last month, said Mel Sorensen, M.D., President and CEO of Galera.
In October 2019, strengthened Galeras leadership team with the appointment of Christopher Degnan as Chief Financial Officer.
Research and development expenses were $11.0 million in the third quarter of 2019, compared to $4.2 million for the same period in 2018.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

SmartStyle Turns to Percona Support to Provide Enhanced Customer Service

Retrieved on:

Tuesday, September 24, 2019

Database management systems, Databases, MySQL, Data management, Percona, XtraDB, Aria, MariaDB, Galera

DURHAM, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Percona , a leader in open source database software and services, today announced that SmartStyle Co., Ltd. , a Japanese solution company specializing in MySQL and a longtime Percona reseller, has signed a Percona Support contract to provide its customers with enhanced support services for Percona Server for MySQL , Percona XtraDB Cluster , MariaDB and MariaDB Galera Cluster.

Key Points:

DURHAM, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Percona , a leader in open source database software and services, today announced that SmartStyle Co., Ltd. , a Japanese solution company specializing in MySQL and a longtime Percona reseller, has signed a Percona Support contract to provide its customers with enhanced support services for Percona Server for MySQL , Percona XtraDB Cluster , MariaDB and MariaDB Galera Cluster.
Perconas technical and sales support services have always been excellent, and in the past, SmartStyle has relied on Percona Support to provide faster issue resolution for complex customer issues.
With the new Percona Support contract, SmartStyle is making it easier for customers to access the industrys top MySQL and MariaDB experts at Percona.
SmartStyle customers will have the option of accessing Percona Support directly or using SmartStyle as a go-between.

SmartStyle Turns to Percona Support to Provide Enhanced Customer Service

Retrieved on:

Tuesday, September 24, 2019

Database management systems, Databases, MySQL, Data management, Percona, XtraDB, Aria, MariaDB, Galera

DURHAM, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Percona , a leader in open source database software and services, today announced that SmartStyle Co., Ltd. , a Japanese solution company specializing in MySQL and a longtime Percona reseller, has signed a Percona Support contract to provide its customers with enhanced support services for Percona Server for MySQL , Percona XtraDB Cluster , MariaDB and MariaDB Galera Cluster.

Key Points:

DURHAM, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Percona , a leader in open source database software and services, today announced that SmartStyle Co., Ltd. , a Japanese solution company specializing in MySQL and a longtime Percona reseller, has signed a Percona Support contract to provide its customers with enhanced support services for Percona Server for MySQL , Percona XtraDB Cluster , MariaDB and MariaDB Galera Cluster.
Perconas technical and sales support services have always been excellent, and in the past, SmartStyle has relied on Percona Support to provide faster issue resolution for complex customer issues.
With the new Percona Support contract, SmartStyle is making it easier for customers to access the industrys top MySQL and MariaDB experts at Percona.
SmartStyle customers will have the option of accessing Percona Support directly or using SmartStyle as a go-between.